SynAct Pharma refines development strategy and extends financial runway through 2026

SynAct Pharma has announced a refined strategic focus for the continued development of its lead compound, resomelagon (AP1189).

The company will pursue two parallel development tracks: early intervention in autoimmune and inflammatory diseases, with primary focus on rheumatoid arthritis (RA), and development of resomelagon as host-directed therapy in viral infections. The aim in both development.